Cargando…
Early experience with teprotumumab for chronic thyroid eye disease
PURPOSE: To report the first case of a patient with chronic thyroid eye disease (TED) treated with teprotumumab. OBSERVATIONS: A 50-year-old female with a 3-year history of Graves’ disease presented with bilateral exophthalmos greatest on the left side. She was followed for 2 years with stable propt...
Autores principales: | Ozzello, Daniel J., Kikkawa, Don O., Korn, Bobby S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7243051/ https://www.ncbi.nlm.nih.gov/pubmed/32462101 http://dx.doi.org/10.1016/j.ajoc.2020.100744 |
Ejemplares similares
-
Thyroid eye disease reactivation associated with COVID-19 vaccination
por: Park, Kathryn S., et al.
Publicado: (2022) -
Teprotumumab in advanced reactivated thyroid eye disease
por: Cheng, Olivia T., et al.
Publicado: (2022) -
Teprotumumab for the treatment of chronic thyroid eye disease
por: Ugradar, Shoaib, et al.
Publicado: (2021) -
Effects of teprotumumab on patients with long-standing, active thyroid eye disease
por: Vinson, Kyle B., et al.
Publicado: (2022) -
Rapidly progressive cognitive decline associated with teprotumumab in thyroid eye disease
por: Hoang, Thanh Duc, et al.
Publicado: (2021)